Propanc Biopharma (PPCB) Gains from Investment Securities (2016 - 2025)
Propanc Biopharma (PPCB) posted quarterly Gains from Investment Securities of -$593710.0 for Q4 2025, up 68.9% quarter-over-quarter from -$1.9 million in Q2 2020.
Propanc Biopharma (PPCB) Gains from Investment Securities (2016 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Gains from Investment Securities for 4 consecutive years, with -$593710.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$593710.0; the TTM figure through Dec 2025 stood at -$2.3 million (changed N/A YoY), while the FY2020 annual figure was $143808.0, down 79.18% from the prior year.
- Gains from Investment Securities advanced to -$593710.0 in Q4 2025 per PPCB's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at -$593710.0 in Q4 2025 and bottomed at -$593710.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -593,710.00 |
| Dec 31, 2025 | -593,710.00 |
| Jun 30, 2020 | -1.91 Mn |
| Jun 30, 2020 | -1.91 Mn |
| Jun 30, 2019 | 201,935.00 |
| Jun 30, 2019 | 201,935.00 |
| Sep 30, 2016 | 21,007.00 |
| Sep 30, 2016 | 21,007.00 |